Overview

Study of Use of Dexmedetomidine for Regional Anesthesia

Status:
Withdrawn
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out the proper amount of a drug called dexmedetomidine added to the local anesthetic drug called lidocaine to prolong the time and effect of pain relief provided for surgery. Dexmedetomidine (trade name Precedex) is approved by U.S. Food and Drug Administration (FDA) and indicated for sedation (calming effect). It has both pain relieving and calming effects when added to lidocaine. In the past, addition of higher amounts of dexmedetomidine to lidocaine decreased blood pressure and heart rate. The investigators plan to study the effect of lower amounts of dexmedetomidine to achieve the same level and duration of pain relief without reduction of blood pressure and heart rate.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine
NYU Langone Health
Treatments:
Dexmedetomidine
Lidocaine